Arvinas Inc. (ARVN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround
Arvinas (ARVN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Arvinas (ARVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?
Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
Arvinas, Inc. ARVN and Pfizer Inc. PFE released topline results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant monotherapy versus fulvestrant in adult patients with advanced or metastatic breast cancer.
Arvinas-Pfizer's breast cancer treatment meets main goal in late-stage study
Pfizer and Arvinas' experimental drug to treat a type of breast cancer met the main goal in a late-stage study, the companies said on Tuesday.
Wall Street Analysts Predict a 228.87% Upside in Arvinas (ARVN): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 228.9% in Arvinas (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy
Arvinas (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
How Much Upside is Left in Arvinas (ARVN)? Wall Street Analysts Think 235.09%
The mean of analysts' price targets for Arvinas (ARVN) points to a 235.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
These Analysts Revise Their Forecasts On Arvinas After Q4 Results
Arvinas, Inc. ARVN reported worse-than-expected fourth-quarter sales results on Tuesday.
Arvinas, Inc. (ARVN) Q4 2024 Earnings Call Transcript
Arvinas, Inc. (NASDAQ:ARVN ) Q4 2024 Earnings Conference Call February 11, 2025 8:00 AM ET Company Participants Jeff Boyle - Vice President of Investor Relations John Houston - President and Chief Executive Officer Noah Berkowitz - Chief Medical Officer Angela Cacace - Chief Scientific Officer Andrew Saik - Chief Financial Officer Conference Call Participants Derek Archila - Wells Fargo & Company Jonathan Miller - Evercore ISI Li Watsek - Cantor Fitzgerald Akash Tewari - Jefferies Group LLC Tazeen Ahmad - Bank of America Srikripa Devarakonda - Truist Securities Jeet Mukherjee - BTIG, LLC Bradley Canino - Stifel Financial Corp. Sudan Loganathan - Stephens Inc. Edward Tenthoff - Piper Sandler Companies Ellie Merle - UBS Group AG Paul Choi - Guggenheim Securities Michael Schmidt - Guggenheim Partners, LLC Operator Good day, and thank you for standing by. Welcome to the Arvinas Fourth Quarter 2024 Earnings Conference Call.
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $2.53 per share a year ago.
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025
Investors looking for stocks that could make dramatic moves in a short, defined time frame will want to turn their attention toward two innovative drugmakers. A couple of stocks in the volatile biopharmaceutical industry are poised to soar by the end of March.
